Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 202CNS 78Genitourinary 52Gastrointestinal 41Lymphoid 34Myeloid 13Dermatologic 13Other solid neoplasm 10Other hematologic neoplasm 8Gynecologic 6Endocrine 5Thoracic 4Head & Neck 3Breast 3Plasma cell 2Classical hematology 1

Conditions

Anemia, Refractory, with Excess of Blasts 255Myelodysplastic Syndromes 228Leukemia, Myeloid, Acute 228Anemia 212Leukemia 205Precursor Cell Lymphoblastic Leukemia-Lymphoma 168Leukemia, Myelomonocytic, Chronic 145Neoplasms 142Leukemia, Lymphocytic, Chronic, B-Cell 116Myeloproliferative Disorders 114Multiple Myeloma 113Lymphoma, Non-Hodgkin 105Thrombocytopenia 100Lymphoma 98Hodgkin Disease 91Anemia, Refractory 81Congenital Abnormalities 77Anemia, Aplastic 77Venous Thromboembolism 76Primary Myelofibrosis 76Lymphoma, Follicular 73Leukemia, Myeloid, Chronic-Phase 70Blast Crisis 67Leukemia, Myelogenous, Chronic, BCR-ABL Positive 65Leukemia, Myeloid, Accelerated Phase 64Lymphoma, Mantle-Cell 63Febrile Neutropenia 62Myelodysplastic-Myeloproliferative Diseases 58Hematologic Neoplasms 56Burkitt Lymphoma 56

Interventions

talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sarcoma, Ewing × Classical hematology × Clear all
NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Pfizer

Phase 1 Completed
113 enrolled 39 charts
BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡